EUCTR2006-006529-25-IT进行中（未招募）1 期
ong-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C. - ND
SCHERING-PLOUGH0 个研究点目标入组 1,954 人开始时间: 2007年4月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,954
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subject must be willing to give written informed consent and be able to adhere to the visit schedule. - Subjects must have received at least one dose of SCH 503034 plus peginterferon alfa-2b with or without ribavirin or peginterferon alfa-2b plus ribavirin in a previous SPRI Phase 2 or 3 clinical study in which SCH 503034 was administered.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concurrent participation in any other clinical study for the treatment of chronic hepatitis C. - Retreatment with any anitviral or immunomodulatory drug for chronic hepatitis C after completion of, or discontinuatio from, the SPRI Phase 2 or 3 clinical study in which the subject previously participated/ - Any condition which on the opinion of the Investigtaor would make the subject unsuitable for enrollment.
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 8.1 Level: LLT Classification code 10019641 Term: Hepatic cirrhosisEUCTR2006-006529-25-FRSchering-Plough Research Institute1,954
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 14.0Level: PTClassification code 10019641Term: Hepatic cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006529-25-DESchering-Plough Research Institute1,954
进行中（未招募）
不适用
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis CEUCTR2006-006529-25-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,800
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 8.1Level: LLTClassification code 10019641Term: Hepatic cirrhosisEUCTR2006-006529-25-NLSchering-Plough Research Institute1,954
已完成
3 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C.Chronic Hepatitis CHepatitis C virus infection10047438NL-OMON35269Schering-Plough9